A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00000980
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: October 1990

November 2, 1999
June 23, 2005
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00000980 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea
Single-Blind Efficacy Evaluation of Intravenous Spiramycin in Subjects With AIDS-Related Cryptosporidial Diarrhea

To determine the safety and effectiveness of intravenous spiramycin in patients with AIDS-related cryptosporidial diarrhea.

Spiramycin, a macrolide antibiotic, has been studied in the United States for the treatment of cryptosporidial diarrhea. Some reports suggest that spiramycin is useful in improving the symptoms of cryptosporidial diarrhea in some patients. Results of one study, however, showed no significant difference between spiramycin and placebo (inactive medication). A later study indicated that the absorption of spiramycin is significantly decreased when food is present. Thus, the results of the trial may have been due to poor absorption of spiramycin.

Spiramycin, a macrolide antibiotic, has been studied in the United States for the treatment of cryptosporidial diarrhea. Some reports suggest that spiramycin is useful in improving the symptoms of cryptosporidial diarrhea in some patients. Results of one study, however, showed no significant difference between spiramycin and placebo (inactive medication). A later study indicated that the absorption of spiramycin is significantly decreased when food is present. Thus, the results of the trial may have been due to poor absorption of spiramycin.

Patients are observed for 3 days to establish baseline conditions. They are informed that the treatment period is 21 days during which they receive 15 days of spiramycin and 6 consecutive days of placebo; they are not told which 6-day period they receive placebo. All patients receive 15 days of spiramycin. Patients who do not have a favorable response are treated with a higher dose of spiramycin for an additional 15 days. Responders at either dose are followed weekly for 4 weeks. Should a relapse occur, patients receive an additional 15 days of therapy, at the dose of spiramycin that initially produced a response, following reestablishment of a baseline with 6 days of placebo. Nonresponders to the higher dose are taken off the study.

Interventional
Phase 1
Primary Purpose: Treatment
  • Cryptosporidiosis
  • HIV Infections
Drug: Spiramycin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
Not Provided
Not Provided

Inclusion Criteria

Concurrent Medication:

Allowed:

  • Vitamin supplements.
  • Zidovudine (AZT) for patients previously taking AZT. However, dosing with spiramycin should be delayed until the dose of AZT has stabilized. The dose may be decreased for AZT-associated toxicity.

Allowed for diarrhea:

  • Loperamide hydrochloride capsules (2 mg) or loperamide hydrochloride liquid (1 mg/5 ml).

Allowed for nausea:

  • Sucralfate and metoclopramide hydrochloride.

Allowed for vomiting:

  • Prochlorperazine and trimethobenzamide hydrochloride.
  • Allowed as prophylaxis for Pneumocystis carinii pneumonia (PCP):
  • Aerosolized pentamidine.

Patients must have:

  • A diagnosis of AIDS according to the CDC.
  • Chronic diarrhea.
  • Presence of Cryptosporidium oocysts in stool specimen. Patients or a legally authorized representative must sign an informed consent form. Diet will be lactose free, maximum 7 g fat/day with unlimited calorie intake. Patients who require total parenteral nutrition will also be allowed oral intake.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

  • Grade 4 (for hematologic) or Grade 3 (for all other) toxicity.
  • Known sensitivity to macrolide antibiotics.
  • Presence of other diarrhea-causing pathogens.
  • Active opportunistic infection requiring systemic antimicrobial therapy.
  • Toxicity grades according to NIAID toxicity scale for adults.

Concurrent Medication:

Excluded:

  • Other investigational drugs.
  • Cancer chemotherapy.
  • Alpha interferon.
  • Other immunomodulating agents.
  • Other macrolide antibiotics.
  • Trimethoprim / sulfamethoxazole.
  • Ganciclovir.
  • H2 blockers and AL-721.
  • Medications known to cause gastrointestinal irritation or alteration of gastrointestinal motility or absorption should be avoided if possible.
  • Zidovudine (AZT) therapy may not be initiated and the dose may not be increased during the study.

Patients with the following are excluded:

  • Grade 4 (for hematologic) or Grade 3 (for all other) toxicity.
  • Known sensitivity to macrolide antibiotics.
  • Presence of other diarrhea-causing pathogens.
  • Active opportunistic infection requiring systemic antimicrobial therapy.
  • Toxicity grades according to NIAID toxicity scale for adults.

Prior Medication:

Excluded within 7 days of study entry:

  • Investigational drugs.

Excluded within 14 days of study entry:

  • Cancer chemotherapy.
  • Alpha interferon.
  • Other immunomodulating agents.
  • Other macrolide antibiotics.
  • Trimethoprim / sulfamethoxazole.
  • Ganciclovir.
Both
13 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00000980
ACTG 113, FDA 28A, CCB-301
Not Provided
Not Provided
Rhone-Poulenc Rorer
National Institute of Allergy and Infectious Diseases (NIAID)
Study Chair: R Soave
National Institute of Allergy and Infectious Diseases (NIAID)
October 1990

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP